GlobalData tracks 18 drugs in development for Atypical Teratoid Rhabdoid Tumor by 16 companies/universities/institutes. The top development phase for Atypical Teratoid Rhabdoid Tumor is preclinical, with six drugs in that stage.
MSD ventures into fibroblast therapies with $1.9bn deal with Mestag – Pharmaceutical Technology
Mestag’s pipeline consists of antibody therapies based on fibroblast-immune interactions as a treatment for cancer and inflammatory diseases. Image credit: Sergiy Palamarchuk / Shutterstock. MSD